Topics

Use of a highly personalized approach to treatment including specific monoclonal antibodies tailored to a patient's biomarker profile improves outcomes for patients with metastatic gastroesophageal cancers, shows research from the University of Chicago.

Sponsor: UltivueIn this Keynote Webinar, sponsored by Illumina, two leading researchers will show how genomic technologies are tackling the COVID-19 pandemic—Alex Greninger, MD, PhD, (University of Washington School of Medicine) and Darrell Dinwiddie PhD, (University of New Mexico Health Sciences Center).

Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A.

Experiments in preclinical models of RCC showed that triple therapy using established treatments plus angiotensin-(1–7) can improve tumor response and significantly prolong survival, suggesting that bolstering ACE2 could improve how patients respond to VEGFR inhibitors, which often lose their effectiveness against cancers over the long term.

Despite previous findings to the contrary, the randomized controlled trial, carried out at the Beneficência Portuguesa Hospital of São Paulo, Brazil found that adding tocilizumab to standard care appeared to increase rather than decrease deaths in COVID-19 patients, leading to the trial being stopped early.

In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients remained alive and six patients had no signs of active disease.

Through its Biclonics platform, Merus aims to produce novel bispecific antibodies that are capable of binding two targets, but which neither require linkers or modifications to force correct pairing of heavy and light chains, nor require fusion proteins to add functionality.

A study carried out by the University of Malta shows that patients with the fatal neurological condition amyotrophic lateral sclerosis have different causative mutations to patients from Northern Europe.

Syntegra uses machine learning to create validated “synthetic data”—replicas of healthcare data that are designed to precisely duplicate its statistical properties, with patient privacy protected by removing all links to the original data.

DARPA identified five disease categories for which the devices should detect pathogens and biomarkers: respiratory illnesses, febrile illnesses, vector-borne illnesses, gastrointestinal illnesses, and sepsis.